This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hassager, C. Articles by Christiansen, C. Search for Related Content PubMed PubMed Citation Articles by Hassager, C. Articles by Christiansen, C.

Circulation, Vol 76, 753-758, Copyright © 1987 by American Heart Association

ARTICLES

The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure

C Hassager, BJ Riis, V Strom, TT Guyene and C Christiansen
Department of Clinical Chemistry, University of Copenhagen, Glostrup Hospital, Denmark.

The long-term effect of percutaneous and oral estrogen replacement therapy on blood pressure, plasma renin substrate, and serum estrogens was examined in a 2 year placebo-controlled study with 110 early postmenopausal women. The women were allocated to four treatment groups: (1) oral cyclical combination of 2 mg estradiol valerate and cyproterone acetate, (2) oral placebo, (3) percutaneous 17 beta- estradiol, supplemented by 200 mg oral progesterone during the second year, or (4) percutaneous placebo cream. Systolic and diastolic blood pressure remained unchanged in both hormone treatment groups, whereas the diastolic blood pressure tended to increase in both placebo groups. Plasma renin substrate increased during oral treatment with estradiol, but remained unchanged with percutaneous estradiol. No correlation was found between blood pressure and plasma renin substrate. During percutaneous administration of estradiol, the serum concentrations of estrone and estradiol continued to rise after 3 months and reached a plateau at 6 months of therapy. Serum estrone but not estradiol showed the same pattern during oral estradiol therapy. No further changes in any of the measured variables were observed in the women treated with percutaneous estradiol after addition of cyclical oral progesterone. We conclude that both oral and percutaneous treatment with estradiol may provide protection against the age-related increase in diastolic blood pressure observed in early postmenopausal women, and that the metabolic steady state is not attained until after 3 months of estradiol therapy.

This article has been cited by other articles:

				J. P. Langrish, N. L. Mills, L. E. Bath, P. Warner, D. J. Webb, C. J. Kelnar, H. O.D. Critchley, D. E. Newby, and W. H. B. Wallace Cardiovascular Effects of Physiological and Standard Sex Steroid Replacement Regimens in Premature Ovarian Failure Hypertension, May 1, 2009; 53(5): 805 - 811. [Abstract] [Full Text] [PDF]

				M. Coylewright, J. F. Reckelhoff, and P. Ouyang Menopause and Hypertension: An Age-Old Debate Hypertension, April 1, 2008; 51(4): 952 - 959. [Full Text] [PDF]

				M. Paul, A. Poyan Mehr, and R. Kreutz Physiology of local Renin-Angiotensin systems. Physiol Rev, July 1, 2006; 86(3): 747 - 803. [Abstract] [Full Text] [PDF]

				P. J. Harvey, B. L. Morris, J. A. Miller, and J. S. Floras Estradiol Induces Discordant Angiotensin and Blood Pressure Responses to Orthostasis in Healthy Postmenopausal Women Hypertension, March 1, 2005; 45(3): 399 - 405. [Abstract] [Full Text] [PDF]

				M. Fischer, A. Baessler, and H. Schunkert Renin angiotensin system and gender differences in the cardiovascular system Cardiovasc Res, February 15, 2002; 53(3): 672 - 677. [Abstract] [Full Text] [PDF]

				R. K. Dubey, S. Oparil, B. Imthurn, and E. K. Jackson Sex hormones and hypertension Cardiovasc Res, February 15, 2002; 53(3): 688 - 708. [Abstract] [Full Text] [PDF]

				R. K. Dubey and E. K. Jackson Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms Am J Physiol Renal Physiol, March 1, 2001; 280(3): F365 - F388. [Abstract] [Full Text] [PDF]

				E. W. Seely, B. W. Walsh, M. D. Gerhard, and G. H. Williams Estradiol With or Without Progesterone and Ambulatory Blood Pressure in Postmenopausal Women Hypertension, May 1, 1999; 33(5): 1190 - 1194. [Abstract] [Full Text] [PDF]

				A. Cagnacci, L. Rovati, A. Zanni, S. Malmusi, F. Facchinetti, and A. Volpe Physiological doses of estradiol decrease nocturnal blood pressure in normotensive postmenopausal women Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1355 - H1360. [Abstract] [Full Text] [PDF]

				M. L Kuroski de Bold Estrogen, natriuretic peptides and the renin-angiotensin system Cardiovasc Res, March 1, 1999; 41(3): 524 - 531. [Abstract] [Full Text] [PDF]

				G. Nickenig, A. T. Baumer, C. Grohe, S. Kahlert, K. Strehlow, S. Rosenkranz, A. Stablein, F. Beckers, J. F. M. Smits, M. J. A. P. Daemen, et al. Estrogen Modulates AT1 Receptor Gene Expression In Vitro and In Vivo Circulation, June 9, 1998; 97(22): 2197 - 2201. [Abstract] [Full Text] [PDF]

				S. K. Gandhi, J. Gainer, D. King, and N. J. Brown Gender Affects Renal Vasoconstrictor Response to Ang I and Ang II Hypertension, January 1, 1998; 31(1): 90 - 96. [Abstract] [Full Text] [PDF]

				K. Sudhir, M. D. Esler, G. L. Jennings, and P. A. Komesaroff Estrogen Supplementation Decreases Norepinephrine-Induced Vasoconstriction and Total Body Norepinephrine Spillover in Perimenopausal Women Hypertension, December 1, 1997; 30(6): 1538 - 1543. [Abstract] [Full Text]

				F. Portaluppi, F. Pansini, R. Manfredini, and G. Mollica Relative Influence of Menopausal Status, Age, and Body Mass Index on Blood Pressure Hypertension, April 1, 1997; 29(4): 976 - 979. [Abstract] [Full Text]

				H. Schunkert, H.-W. Hense, A. Gimenez-Roqueplo, J. Stieber, U. Keil, G. A.J. Riegger, and X. Jeunemaitre The Angiotensinogen T235 Variant and the Use of Antihypertensive Drugs in a Population-Based Cohort Hypertension, February 1, 1997; 29(2): 628 - 633. [Abstract] [Full Text]

				H. Schunkert, A.H. J. Danser, H.-W. Hense, F. H.M. Derkx, S. Kurzinger, and G. A.J. Riegger Effects of Estrogen Replacement Therapy on the Renin-Angiotensin System in Postmenopausal Women Circulation, January 7, 1997; 95(1): 39 - 45. [Abstract] [Full Text]

				The Writing Group for the PEPI Trial, V. T. Miller, J. LaRosa, V. Barnabei, C. Kessler, G. Levin, A. Smith-Roth, M. Griffin, D. B. Stoy, T. Bush, et al. Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA, January 18, 1995; 273(3): 199 - 208. [Abstract] [PDF]

				ESTROGENS MAY LOWER BLOOD PRESSURE Journal Watch (General), October 30, 1987; 1987(1030): 3 - 3. [Full Text]